Holen Sie sich die Stockscreener-App
91.61
1.55%
1.40
Vorhandelsmarkt:
91.61
Schlusskurs vom Vortag:
$90.21
Offen:
$90.29
24-Stunden-Volumen:
1.17M
Relative Volume:
1.03
Marktkapitalisierung:
$9.83B
Einnahmen:
$769.10M
Nettoeinkommen (Verlust:
$46.67M
KGV:
261.74
EPS:
0.35
Netto-Cashflow:
$119.79M
1W Leistung:
+4.23%
1M Leistung:
+26.15%
6M Leistung:
+156.04%
1J Leistung:
+26.76%
1-Tages-Spanne:
$89.73
$92.83
1-Wochen-Bereich:
$86.04
$92.83
52-Wochen-Spanne:
$28.66
$92.83
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
91.61 | 9.33B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2026-03-26 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | Eingeleitet | UBS | Neutral |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-06 | Hochstufung | Truist | Hold → Buy |
| 2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
| 2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-01 | Herabstufung | Truist | Buy → Hold |
| 2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-09-24 | Eingeleitet | Jefferies | Buy |
| 2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Bestätigt | Stifel | Hold |
| 2018-05-31 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Eingeleitet | Stifel | Buy |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-04-21 | Eingeleitet | FBR Capital | Outperform |
| 2014-01-13 | Herabstufung | Stifel | Buy → Hold |
| 2013-08-09 | Herabstufung | Janney | Buy → Neutral |
| 2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
CORTCorcept Therapeutics Inc Volatility & Greeks - Finviz
Price to sales forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally - Stocktwits
Enterprise value to revenue forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Price to earnings forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Corcept sinks after FDA rejects drug to treat hypertension - MSN
Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Defensive Index - marketscreener.com
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
CORT Stock Skyrockets 35% After Early FDA Nod For Ovarian Cancer Drug - Stocktwits
Corcept gives FDA new relacorilant data in resubmitted application - Cushing's Disease News
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm - PR Newswire
Number of shareholders of Corcept Therapeutics Incorporated. – BX:HTD - TradingView
Corcept Therapeutics Incorporated. Actuals & Estimates (NASDAQ:CORT) - TradingView
HTD Forecast — Price Target — Prediction for 2027 - TradingView
Corcept Therapeutics Inc (CORT) Institutional Confidence - TradingKey
Corcept Therapeutics Inc (CORT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corcept Therapeutics Inc (CORT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CORT News | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Corcept Therapeutics Inc (CORT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Corcept Therapeutics Inc (CORT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corcept Therapeutics Inc (CORT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Trust linked to Corcept (NASDAQ: CORT) director sells 10,000 shares in plan - Stock Titan
Corcept (CORT) director’s entities report 20K-share sale and large holdings - Stock Titan
Wolfe Research Upgrades Corcept Therapeutics (CORT) to Peer Perf - GuruFocus
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Corcept Therapeutics Inc (CORT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome - Business Wire
Corcept Therapeutics Inc (CORT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Corcept Therapeutics (CORT) Resubmits NDA for Relacorilant with New Data - GuruFocus
Corcept Therapeutics (CORT) Resubmits Drug Application for Cushi - GuruFocus
Corcept Therapeutics (CORT) resubmits FDA NDA for relacorilant in Cushing’s syndrome - Stock Titan
Corcept Therapeutics(CORT.US) Officer Sells US$3.25 Million in Common Stock - Moomoo
Corcept Therapeutics (CORT) CFO exercises options, sells 40,000 shares in 10b5-1 trades - Stock Titan
Charles Schwab (NASDAQ: CORT) files Form 144 listing 20,000 shares - Stock Titan
[144] CORCEPT THERAPEUTICS INC SEC Filing - Stock Titan
Korlym improves results for diabetes patients taking GLP-1 drugs - Cushing's Disease News
Catalyst and Momentum Trials Data Fuels Optimism for Corcept Therapeutics (CORT) - Yahoo Finance
Norges Bank Purchases New Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Clearbridge Investments LLC Has $17.66 Million Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT to resubmit NDA for relacorilant in Cushing's syndrome, stock up - MSN
7 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
CORT Stock Rises 42% in a Month: Here's What You Should Know - The Globe and Mail
Corcept Therapeutics (CORT) Reveals Promising Trial Data on Diab - GuruFocus
Corcept Therapeutics (CORT) Reveals Promising Trial Data on Diabetes Treatment - GuruFocus
Geode Capital Management LLC Acquires 734,646 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym® - Lelezard
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Corcept Therapeutics Inc-Aktie (CORT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MAHONEY DAVID L | Director |
Jun 17 '26 |
Sale |
84.53 |
20,000 |
1,690,506 |
26,147 |
| Mokari Atabak | Chief Financial Officer |
Jun 15 '26 |
Option Exercise |
19.26 |
40,000 |
770,400 |
56,130 |
| Mokari Atabak | Chief Financial Officer |
Jun 15 '26 |
Sale |
81.15 |
40,000 |
3,245,900 |
16,130 |
0.05%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):